Methylergonovine Maleate
Brand Names: Methergine
Methodology & AI Transparency ⓘ
Methylergonovine Maleate Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Indications and usage: Following delivery of placenta, for routine management of uterine atony, hemorrhage and subinvolution of the uterus.
- 2 Real-world patient consensus: 87% patient "Worth It" rating across 12 anonymous logs for Methylergonovine Maleate (RxNorm 996824).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $125.64 wholesale mail-order against $307.82 retail pharmacy pricing.
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Methylergonovine Maleate): nausea (10.6%), headache (9.2%), dizziness (8.5%).
Ask our AI Specialists anything about Methylergonovine Maleate
Methylergonovine Maleate Mechanism, CYP450 Pathways & DailyMed Monograph
Indications and usage: Following delivery of placenta, for routine management of uterine atony, hemorrhage and subinvolution of the uterus. For control of uterine hemorrhage in the second stage of labor following delivery of the anterior shoulder.
CLINICAL PHARMACOLOGY Methergine (methylergonovine maleate) acts directly on the smooth muscle of the uterus and increases the tone, rate, and amplitude of rhythmic contractions. Thus, it induces a rapid and sustained tetanic uterotonic effect which shortens the third stage of labor and reduces blood loss. The onset of action after I.V. administration is immediate; after I.M. administration, 2-5 minutes, and after oral administration, 5-10 minutes. Pharmacokinetic studies following an I.V. injection have shown that methylergonovine is rapidly distributed from plasma to peripheral tissues within 2-3 minutes or less.
With Terminal t½ estimated at 10–15 hrs depending on renal/hepatic reserve (Methylergonovine Maleate) residence kinetics and Complete (~100%) parenteral systemic delivery for Methylergonovine Maleate (.2 mg/mL Injection, Solution) bioavailability, Methylergonovine Maleate undergoes mixed metabolic conjugation and unchanged urinary excretion across methylergonovine maleate regimens and establishes therapeutic activity over rapid intravascular/parenteral onset within 15–45 minutes after methylergonovine maleate administration.
Standard adult regimens span .2 mg/mL Injection, Solution, .2 mg/1 Tablet, .2 mg/mL Injection, 0.2mg Tablet. Prescribers screen specifically against contraindications hypertension; and hypersensitivity., while community micro-logs most frequently note nausea (10.6% of reports), headache (9.2% of reports), dizziness (8.5% of reports).
Avoid overlapping ergot derivative prescriptions alongside Methylergonovine Maleate to prevent cumulative receptor toxicity.
Unstandardized herbal extracts may interact pharmacodynamically with Methylergonovine Maleate maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- CONTRAINDICATIONS Hypertension
- and hypersensitivity.
Logged Side-Effect Incidence (12 Reports)
Methylergonovine Maleate Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Methylergonovine Maleate)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Misoprostol with and without methylergometrine and oxytocin in outpatient medical The effectiveness of the drugs in the two drug groups combined with oxytocin and methylergometrine is higher than the misoprostol group alone. BMC research notes • 2023-10-05 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 37798748 ↗ |
Methylergonovine Maleate Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $4.3506/unit (~$130.52/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $125.64 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $307.82 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 12 Anonymous DotMD Community Micro-Logs | $144.49 / mo | View logs ↓ |
Methylergonovine Maleate Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Methylergonovine Maleate RxNorm Concept ID | 996824 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $4.3506 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $307.82 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $125.64 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 87.00% Worth It (12 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Methylergonovine Maleate Patient Community, Cohort Filters & Dosage Logs
Deterministic Methylergonovine Maleate reference combining NIH RxNorm (996824), Medicaid NADAC ($4.3506/unit), and anonymous cohort outcomes (87% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Methylergonovine Maleate community threads and patient logs by age, biological sex, dosage, and treatment duration.